Open Biosystems, Inc., focused on the commercialization of leading-edge life science research tools for drug discovery, announced today its Open Access RNAi Program. Participation in this program allows all research laboratories within an institution access to its choice of Open Biosystems' portfolio of genome-wide RNAi resources. The Open Access RNAi Program, unique in this field, supports Open Biosystems' vision of supporting basic and medical research and reinforces its commitment to expanding access to research reagents for the life sciences community.
